Lung cancer vaccine

An injection of a BioNTech mRNA cancer immunotherapy for non-small cell lung cancer (NSCLC) - known as BNT116 - at the University College London Hospital clinical research facility in central London, as part of the first clinical trial for the lung cancer immunotherapy in the UK. Mr Racz, a 67-year-old scientist who moved from Poland to London a decade ago, was diagnosed with lung cancer in May and has been treated with chemotherapy and radiotherapy ahead of receiving lung cancer vaccine. Approximately 130 participants will be enrolled in the study across 34 research sites in seven countries, with six UK sites selected. Picture date: Tuesday August 20, 2024. (Photo by Aaron Chown/PA Images via Getty Images)